NBIX•benzinga•
RBC Capital Upgrades Neurocrine Biosciences to Outperform, Lowers Price Target to $137
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 14, 2025 by benzinga